Mechanism of Action

SEM-O® (semaglutide) is a once-daily oral GLP-1 receptor agonist enabled by SNAC technology for systemic metabolic effects.

GLP-1 Receptor Activation

Semaglutide selectively activates the glucagon-like peptide-1 (GLP-1) receptor, a key incretin pathway involved in glucose and appetite regulation.

Mimics endogenous GLP-1 activity
Enhances glucose-dependent insulin secretion
Suppresses inappropriate glucagon release
Regulates appetite and gastric motility

Impact on Different Areas of the Body

Pancreas

Brain & Appetite Control

Gastrointestinal Tract

Cardiometabolic Effects

Semaglutide improves pancreatic hormone regulation in a glucose-dependent manner.

Increases insulin secretion when blood glucose is elevated
Suppresses excess glucagon secretion
Reduces fasting and post-prandial plasma glucose levels

Integrated Clinical Effect

SEM-O® delivers GLP-1–mediated metabolic regulation across pancreatic, central, gastrointestinal, and cardiometabolic pathways, enabled by SNAC absorption technology.

Drug Delivery & Administration

SEM-O® is formulated for once-daily oral administration.

Oral tablet containing semaglutide with SNAC
Systemic exposure achieved via gastric absorption
Provides a non-injectable GLP-1 therapy option
Suitable for patients preferring oral treatment